Bevacizumab Against Recurrent Retinal Detachment (BEARRD)

University of Wisconsin (UW)

Status and phase: Completed; Phase 2

Conditions: Proliferative Vitreoretinopathy; Retinal Detachment

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT02192970

A536070 (Other Identifier)

2014-0931

SMPH/OPHTHAL&VIS SCI (Other Identifier)

Details and patient eligibility

About

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Enrollment: 101 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years
• Eyes with rhegmatogenous retinal detachment

Exclusion criteria

• Presence of PVR
• Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.
• Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
• Secondary retinal detachment repair
• Use of silicone oil as tamponade agent
• Patients less than 18 years of age
• Pregnancy
• Known allergy or contraindication to intravitreal bevacizumab

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

101 participants in 2 patient groups

Bevacizumab

Experimental group

Description:

Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.

Treatment:

Drug: Bevacizumab

Chart review

No Intervention group

Description:

Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.